

## ASX ANNOUNCEMENT

### HEPATITIS C TRIAL TO PROCEED

**Sydney Australia, 14th January 2014:** RNAi-based therapeutics company Benitec Biopharma Limited (ASX: BLT) today announced that the US Food and Drug Administration (FDA) has advised the Company that it may proceed with its ‘first in man’ clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat Hepatitis C with a single injection.

This follows the FDA’s review of Benitec’s Investigational New Drug (IND) application, which was filed on 6 December 2013.

Benitec Biopharma’s CEO and Managing Director, Peter French said, “We are very pleased with this outcome which establishes Benitec as a clinical stage company.”

For further information, please contact the persons outlined below, or visit the Benitec website at [www.benitec.com](http://www.benitec.com).

<i>Company</i>	<i>Investor relations</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: <a href="mailto:cstubbings@benitec.com">cstubbings@benitec.com</a>	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: <a href="mailto:jlowe@buchanwe.com.au">jlowe@buchanwe.com.au</a>

#### ***About Benitec Biopharma Limited:***

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington’s disease. For more information on Benitec refer to the Company’s website at [www.benitec.com](http://www.benitec.com).